Erratum: Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme (Journal of Neuro-Oncology (2008) vol. 89 (339-357) 10.1007/s11060-008-9615-4);Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 89, Issue 3, 2008, Pages 339-357

  Fadul, Camilo E ^a   Wen, Patrick Y ^b   Kim, Lyndon ^c   Olson, Jeffrey J ^d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; BIOPOLYMER; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISONIDAZOLE; NIMUSTINE; NITROSOUREA DERIVATIVE; PLACEBO; PROCARBAZINE; STREPTOZOCIN; TEMOZOLOMIDE; TENIPOSIDE; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; EVIDENCE BASED MEDICINE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LUNG TOXICITY; MEDICAL LITERATURE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PROGNOSIS; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 50449099720     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9776-1     Document Type: Erratum

References (80)

1. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52:997-1007
2. Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K, Yamamoto S, Kageyama N, Handa H, Mogami H, Nishimoto A, Uozumi T, Matsutani M, Nomura K (1986) Effects of ACNU and radiotherapy on malignant gliomas. J Neurosurg 64:53-57
3. Medical Research Council Brain Tumour Working Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A medical research council trial. J Clin Oncol 19:509-518
4. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner J, Gilbert M, Newton HB, Hellman R (2003) Carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group trial 2394. J Clin Oncol 21:1485-1491
5. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597
6. Lai R, Chu R, Fraumeni M, Thabane L (2006) Quality of randomized controlled trials reporting in the primary treatment of brain tumors. J Clin Oncol 24:1136-1144
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cainrcross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987-996
8. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. New Eng J Med 352:997-1003
9. Bullock R, Chestnut RM, Clifton G, Ghajar J, Marion DW, Narayan RK, Newell DW, Pitts LH, Rosner MJ, Wilberger JW (1996) Guidelines for the management of severe head injury: Brain Trauma Foundation. Eur J Emerg Med 3:109-127
10. Walters BC (1998) Clinical practice parameter development in neurosurgery. In: Bean JR (ed) NeurTsurgery in transition: the socioeconomic transformation of neurological surgery. Williams and Wilkins, Baltimore, pp 99-111
11. Glioma Meta-analysis Trialists Group (2002) Chemotherapy in adult high-grade gliomas: A systemic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018
12. Deutsch M, Green SB, Strike TA, Burger PC, Robertson JT, Selker RG, Shapiro WR, Mealey J Jr, Ransohoff JII, Paoletti P, Smith KR Jr, Odom GL, Hunt WE, Young B, Alexander E Jr, Walker MD, Pistenmaa DA (1989) Results of a randomized tiral comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, and BCMU following misonidazole plus radiotherapy in the postoperative treatment of malignant gliomas. Int J Radiat Oncol Biol Phys 16:1389-1396
13. Dinapoli R, Brown LD, Arusell RM, Earle JD, O'Fallon JR, Buckner JC, Scheithauer BW, Krook JE, Tschetter LK, Maier JA, Pfeifle DM, Gesme DJ Jr (1993) Phase III comparative evaluation PCNU and carmustine combined with radiation therapy for high-grade-glioma. J Clin Oncol 11:1316-1321
14. Stupp R, Dietrich PY et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20(5):1375-1382
15. Weller M, Muller B, Koch R, Bamberg M, Krauseneck P, Neuro-Oncology Working Group of the German Cancer Society (2003) Neuro-oncology working group 01 Trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant gliomas. J Clin Oncol 21:3276-3284
16. DerSimonian R, Laird N (1986) Meta-analysis of clinical trials. Control Clin Trials 7:177-188
17. Piedbois P (2004) Meta-analysis based on abstracted data: A step in the right direction, but only a first step. J Clin Oncol 19:3839-3841
18. Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro-Oncology 6:227-235
19. Lai R, Rong C, Fraumeni M, Thabane L (2006) Quality of randomized controlled trials reporting the primary treatment of brain tumors. J Clin Oncol 24:1136-1144
20. Moher E, Schulz DF, Altman DG (2001) The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 357:1191-1194
21. Halperin EC, Herndon J, Schold SC, Brown M, Vick N, Cairncross JG, Macdonald DR, Gaspar L, Fischer B, Dropcho E, Rosenfeld S, Morowitz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Paleologos N, Burger P, Bentel GC, Friedman A (1996) A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. Int J Radiat Oncol Biol Phys 34:793-802
22. Mahaley MS Jr, Whaley RA, Krigman MRE, Bouldin TW, Bertsch L, Cush S (1987) Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas. Surg Neurol 27:430-432
23. Hatlevoll R, Lindegaard KR, Hagen S, Kristiansen K, Nesbakken R, Torvik A, Ganz JC, Mella O, Rosengren B, Ringkjob R, Arnasson O, Lindgren S, Lipecki M, Notter G, Littbrand B, Saterborg NE, Benediktsson G, Johansson L, Spannare B, Brun A, Berthelsen A, Busch H, Gronbaek E, Rygard J, Haase JP, Lambrethsen E, Midholm S, Sehested P, Heikkinen M, Nystrom S, Taskinen P, Mantyla M, Elgen K, Aaskoven O, DeGaris ST, Jensen RH, Matheson I (1985) Combined modality treatment of operated astrocytomas grade 3 and 4. Cancer 56:41-47
24. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Andersen AP, Elgen E (1981) Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and the lack of potentiation of bleomycin on survival time. Cancer 47:649-652
25. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Manaley JS, Mealey J Jr, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329
26. Walker MD, Alexander E, Hunt WE, Leventhal CM, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA (1976) Evaluation of mithramycin in the treatment of anaplastic gliomas. J Neurosurg 44:655-667
27. Shapiro WR, Green SR, Burger PC, Mahaley MS, Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J Jr, Strike TA, Pistenmaa DA (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001: J Neurosurg 71:1-9
28. Shapiro WM, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, Mahaley MS (1992) A randomized comparison of intra-arterial versus intravenous BCNU with or without intravenous 5-fluorouracil for newly diagnosed patients with malignant glioma. J Neurosurg 76:772-781
29. Schold C Jr, Herndon JE, Burger PC, Halperin EC, Vick NA, Carincross JG, Macdonald DR, Dropcho EJ, Morawetz R, Bigner DD, Mahaley MS Jr (1993) Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. J Clin Oncol 11:77-83
30. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44:1479-1483
31. Afra D, Kerpel-Fronius S, Szinai I, Koesis B, Eckhardt S (1990) Combined treatment of anaplastic astrocytoma (grade 3-4) with diacetyl-dianhydro-galactitol. J Neurooncol 8:85-91
32. Fountzilas G, Karavelis A, Makrantonakis P, Selviaridis P, Tzizikas J, Kalogera-Fountzila A, Hatzibaloglou A, Karkavelas G, Foroglou G, Tourkantonis A (1997) Concurrent radiation and intracarotid cisplatin infusion in malignant gliomas: A feasibility study. Am J Clin Oncol 20:138-142
33. Lunardi P, Farah JO, Mastronardi L, Puzzilli F, Lo Bianco FM (1996) Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: A phase II study. Acta Neurochir 138:215-220
34. Mastronardi L, Puzzilli F, Couldwell WT, Farah JO, Lunardi P (1998) Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients. J Neurooncol 38:59-68
35. Lassen U, Kristjansen PEG, Wagner A, Kostel-janetz M, Poulsen HS (1999) Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J Neurooncol 43:161-166
36. Wick W, Hermisson M, Kortmann RD, Kuker WM, Duffner F, Dichgans J, Bamberg M, Weller M (2002) Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma. A phase II study. J Neurooncol 59:151-155
37. Kuratsu J, Arita N, Kayama T, Kubo N, Sawamura Y, Ushio Y (2000) Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients. J Neurooncol 48:145-149
38. Weller M, Streffer J, Wick W, Kortmann RD, Heiss E, Kuker W, Meyermann R, Dichgans J, Bamberg M (2001) Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. Cancer 91:423-427
39. Choi IS, Lee SH, Kim TY, Bang JS, Paik SH, Kim S, Kim IH, Heo DS, Bang YJ, Kim DG, Jun HW, Kim NK (2002) Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 60:171-176
40. Calvo FA, Dy C, Henriquez I, Hidalgo V, Bilbao I, Santos M (1987) Postoperative radical radiotherapy with concurrent weekly intra-arterial cis-platinum for treatment of malignant glioma: A pilot study. Radiother Oncol 14:83-88
41. Brandes AA, Rigon A, Zamieri P, Scelzi E, Amsita P, Berti F, Rotilio A, Gardiman M, Fiorentino MV (1996) Early chemotherapy and concurrent radiochemotherapy in high grade glioma. J Neurooncol 30:247-255
42. Shinoda J, Sakai N, Hara A, Ueda T, Sadai H, Nakatani K (1997) Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme - A pilot study. J Neurooncol 35:73-80
43. Levin VA, Maor MH, Thall PF, Yung WKA, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L, Gleason MJ (1995) Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Rad Oncol Biol Phys 33:357-364
44. Larner JM, Phillips CD, Dion JE, Jensen ME, Newman SA, Jane JA (1995) A phase 1-2 trial of superselective carboplatin and low-dose infusional 5-fluorouracil and concurrent radiation for high grade gliomas. Am J Clin Oncol 18:1-7
45. Fernandez-Hidalgo OA, Vanaclocha V, Vieitez JM, Aristu JJ, Rebollo J, Gurpide A, Aramendia JM, Moreno-Palanques R, Martin-Algarra S, Subira ML, Brugarolas A (1996) High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: Benefit for selected patients. Bone Marrow Transpl 18:143-149
46. Jeremic B, Shibamoto Y, Grujicic D, Stojanovic M, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J (2001) Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: Long-term results of a phase II study. J Neurooncol 51:133-141
47. Peterson K, Harsh G, Fisher PG, Adler J, Le Q (2001) Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma. J Neurooncol 53:27-32
48. Muanza T, Shenouda G, Souhami L, Leblanc R, Mohr G, Corns R, Langleben A (2000) High dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: A phase Ib study. Can J Neurol Sci 27:302-306
49. Schuck A, Muller SB, Kohler A, Donemann S, Weinstroer M, Mosler C, Rube CE, Wassmann H, Willich N, Rube C (2002) Combined radiochemotherapy with paclitaxel in the treatment of malignant glioma. Strahlenther Onkol 178:486-490
50. Vinolas N, Gil M, Verger E, Villa S, Pujol T, Ceral L, Garcia M, Graus F (2002) Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: A phase II study. Anticancer Drugs 13:163-167
51. Bashir R, Hochberg FH, Linggood RM, Hottleman K (1988) Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. J Neurosurg 68:917-919
52. Buckner JC, Schomberg PJ, McGinnis WL, Cascino TL, Scheithauer W, O'Fallon JR, Morton RF, Kuross SA, Mailliard JA, Hatfield AK, Cole JU, Steen PD, Bernath AM (2001) A phase III study of radiation therapy plus carmustine with or without recombinant interferon-α in the treatment of patients with newly diagnosed high grade glioma. Cancer 92:420-433
53. Avellanosa AM, West CR, Tsukada Y, Higby DJ, Bakshi S, Reese PA, Jennings E (1979) Chemotherapy of nonirradiated malignant gliomas. Phase II: Study of the combination of methyl-CCNU, vincristine, and procarbazine. Cancer 44:839-846
54. Wolff SN, Phillips GL, Herzig GP (1987) High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high grade gliomas of the central nervous system. Cancer Treat Rep 71:183-185
55. Balana C, Ramirz JL, Taron M, Roussos Y, Ariza A, Ballester R, Sarries C, Mendez P, Sanchez JJ, Rosell R (2003) O-6 methylguanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1, 3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9:1461-1468
56. Tanaka S, Kamitani H, Amin MR, Watanabe T, Oka H, Fujii K, Nagashima T, Hori T (2000) Preliminary individual adjuvant therapy for gliomas based on the results of molecular analyses for drug resistance genes. J Neurooncol 46:157-171
57. Iwadate Y, Fujimoto S, Namba H, Yamaura A (2003) Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing. Br J Cancer 89:1896-1900
58. Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208-2214
59. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389
60. Villa S, Vinolas N, Verger E, Yaya R, Martinez A, Gil M et al (1998) Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys 42(5):977-980
61. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo J-S, Jadaud E, Colin P, Bondiau P-Y, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron J-J, Bissery A, Delattre J-Y (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527-1535
62. Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A et al (2003) A prospective study on glioblastoma in the elderly. Cancer 97:657-662
63. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262-2266
64. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T (1997) Interstitial chemotherapy with carmustine-loaded polymers for high grade gliomas: A randomized double-blind study. Neurosurgery 41:44-49
65. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmistine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomas. Neuro Oncol 5:79-88
66. Sheleg SV, Korotkevich EA, Zhavrid EA, Muravskaya GV, Smeyanovich AF, Shanko YG, Yurkshtovich TL, Bychkovsky PB, Belyaev SA (2002) Local chemotherapy with ciplatin-depot for glioblastoma multiforme. J Neurooncol 60:53-59
67. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher AL, Wessels BW, Carpenter SP, Shan JS (2005) Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 56:1243-1252
68. Quinn JA, Desjardins A, Weingart J et al (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178-7187
69. Barvaux VA, Ranson M, Brown R et al (2004) Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther 3:123-127
70. Woolford LB, Southgate TD, Margison GP et al (2006) The P140 K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. J Gene Med 8:29-34
71. Plummer R, Middleton M, Wilson R, et al (2005) Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Abstr B268
72. Tentori L, Graziani G (2005) Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52(1):25-33
73. Tentori L, Leonetti C, Scarsella M et al (2005) Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol 26:415-422
74. Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr, Ewend MG (2003) Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61:187-196
75. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5(4):297-309
76. Kesari S, Ramakrishna N, Sauvageot C, Stiles C, Wen PY (2006) Targeted molecular therapies for recurrent malignant glioma. Curr Oncol Reports 8:58-70
77. Wen PY, Kesari S, Drappatz J (2006) Malignant gliomas: Strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther 6:733-754
78. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC (2004) PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55:426-432
79. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ (2007) Vandetanib (ZD6474): An orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239-249
80. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T et al (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585-1592